|14th December 2020||David R Guyer||9,270||Open or private sale||$7.16||$66,373.20|
|14th December 2020||Keith Westby||4,527||Open or private sale||$7.16||$32,413.32|
|12th December 2020||David R Guyer||17,200||Exercise of derivative||$0.00|
|12th December 2020||Glenn Sblendorio||22,950||Exercise of derivative||$0.00|
|12th December 2020||David Francis Carroll||12,500||Exercise of derivative||$0.00|
|12th December 2020||Keith Westby||12,500||Exercise of derivative||$0.00|
|10th December 2020||David R Guyer||9,602||Open or private sale||$6.96||$66,829.92|
|10th December 2020||Keith Westby||3,676||Open or private sale||$6.96||$25,584.96|
|9th December 2020||David Francis Carroll||10,000||Exercise of derivative||$0.00|
|9th December 2020||Keith Westby||10,000||Exercise of derivative||$0.00|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.
The company is developing novel therapeutics to treat diseases of the eye. The company is based in San Francisco and has offices in New York and London.